In a similar vein, one of the best-known American stem cell scientists, John Gearhart, of Johns Hopkins University, in Baltimore, writes in the New England Journal of Medicine that "reprogramming of adult cells to generate patient-specific therapies represents the future for stem-cell biologists." However, unlike Grompe, he insists that research on embryos must proceed. "Such cells remain the gold standard for determining the molecular basis of human tissue development and for developing cell-based therapies for human diseases."